Laboratorios Farmaceuticos Rovi, S.A. Share Price

Equities

ROVI

ES0157261019

Pharmaceuticals

Market Closed - BME 09:05:26 26/04/2024 pm IST 5-day change 1st Jan Change
85 EUR +0.35% Intraday chart for Laboratorios Farmaceuticos Rovi, S.A. +7.05% +41.20%

Financials

Sales 2024 * 824M 881M 73.52B Sales 2025 * 906M 969M 80.84B Capitalization 4.4B 4.71B 393B
Net income 2024 * 171M 183M 15.25B Net income 2025 * 206M 220M 18.37B EV / Sales 2024 * 5.3 x
Net cash position 2024 * 38.02M 40.66M 3.39B Net cash position 2025 * 139M 148M 12.36B EV / Sales 2025 * 4.71 x
P/E ratio 2024 *
26.5 x
P/E ratio 2025 *
22.3 x
Employees 1,925
Yield 2024 *
1.32%
Yield 2025 *
1.52%
Free-Float 35.68%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Laboratorios Farmaceuticos Rovi, S.A.

1 day+0.35%
1 week+7.05%
Current month+5.07%
1 month+6.05%
3 months+31.27%
6 months+72.27%
Current year+41.20%
More quotes
1 week
78.60
Extreme 78.6
86.90
1 month
77.75
Extreme 77.75
86.90
Current year
60.35
Extreme 60.35
86.90
1 year
37.96
Extreme 37.96
86.90
3 years
35.20
Extreme 35.2
86.90
5 years
17.30
Extreme 17.3
86.90
10 years
7.90
Extreme 7.9
86.90
More quotes
Managers TitleAgeSince
Chief Executive Officer - 01/94/01
Director of Finance/CFO - 01/00/01
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - 01/95/01
Director of Finance/CFO - 01/00/01
Chief Executive Officer - 01/94/01
More insiders
Date Price Change Volume
26/24/26 85 +0.35% 79,264
25/24/25 84.7 +6.41% 159,176
24/24/24 79.6 -1.06% 113,717
23/24/23 80.45 +1.26% 36,685
22/24/22 79.45 +0.06% 37,668

Delayed Quote BME, April 26, 2024 at 09:05 pm IST

More quotes
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - pharmaceutical products manufactured under contract (49%); - prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%). Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
85 EUR
Average target price
84.1 EUR
Spread / Average Target
-1.06%
Consensus

Quarterly revenue - Rate of surprise